FERRO, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 430
EU - Europa 111
AS - Asia 88
SA - Sud America 4
AF - Africa 1
Totale 634
Nazione #
US - Stati Uniti d'America 430
SG - Singapore 53
IT - Italia 35
CN - Cina 25
DE - Germania 21
SE - Svezia 17
FI - Finlandia 10
GB - Regno Unito 8
FR - Francia 7
RU - Federazione Russa 6
BR - Brasile 3
HK - Hong Kong 3
IN - India 3
CH - Svizzera 2
LT - Lituania 2
TR - Turchia 2
AR - Argentina 1
CI - Costa d'Avorio 1
IE - Irlanda 1
IQ - Iraq 1
NL - Olanda 1
PL - Polonia 1
UZ - Uzbekistan 1
Totale 634
Città #
Fairfield 82
Chandler 68
Santa Clara 27
Cambridge 23
Woodbridge 23
Ashburn 21
Houston 21
Singapore 19
Padova 17
San Diego 11
Helsinki 10
Seattle 10
Boardman 9
Medford 9
Princeton 9
Ann Arbor 8
Des Moines 8
Wilmington 8
Columbus 6
Roxbury 6
Beijing 5
Falkenstein 4
New York 4
Hong Kong 3
London 3
Ogden 3
Pune 3
Belluno 2
Duncan 2
Hounslow 2
Munich 2
Nuremberg 2
Pignone 2
Portland 2
Abidjan 1
Amsterdam 1
Ankara 1
Cabrobó 1
Catamarca 1
Dallas 1
Dois Lajeados 1
Dublin 1
Frankfurt am Main 1
Guangzhou 1
Guarulhos 1
Gunzenhausen 1
Jolanda di Savoia 1
Los Angeles 1
Maida Vale 1
Milan 1
New Bedfont 1
Norwalk 1
Seregno 1
Shanghai 1
Tashkent 1
Torreglia 1
Treviso 1
Washington 1
Xi'an 1
Zonguldak 1
Totale 460
Nome #
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 87
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 82
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 82
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 80
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 73
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 73
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 65
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience 59
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report 47
Totale 648
Categoria #
all - tutte 4.015
article - articoli 4.015
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.030


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202167 0 0 0 0 0 31 9 2 7 3 1 14
2021/2022225 9 24 41 4 15 35 30 6 8 10 12 31
2022/2023121 23 19 3 17 10 11 1 9 21 4 3 0
2023/202485 11 9 14 7 7 14 5 1 4 3 5 5
2024/2025150 0 12 21 11 41 7 3 37 17 1 0 0
Totale 648